Kornimate/medical-research-clean huggingface dataset:
a research study to see how well cagrisema helps people in china with excess body weight lose weight

Conditions: Obesity or Overweight

Summary: this study will look at how well the new medicine cagrisema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. participants will either get cagrisema, a dummy medicine or semaglutide. which treatment participants get is decided by chance. participants will take one injection once a week. the study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. the study will last for about 1 year.


Eligibility criteria:
inclusion criteria: * male or female * age above or equal to 18 years at the time of signing informed consent 1. body mass index (bmi) greater than or equal to 30.0 kilograms per square meter (kg/m\^2) or 2. bmi greater than or equal to 27.0 kg/m\^2 with the presence of at least one weight-related comorbidity including, but not limited to, type 2 diabetes mellitus, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease for participants with type 2 diabetes (t2d) at screening the following criteria also apply: * diagnosed with type 2 diabetes mellitus greater than equal to 180 days before screening * treatment with either lifestyle intervention, or treatment with 1-3 marketed oral antidiabetic drugs (oads) (metformin, α-glucosidase inhibitors (agi), glinides, sodium-glucose cotransporter 2 inhibitor (sglt2i)), thiazolidinediones, or sulphonylureas (sus) as a single agent or in combination) according to local label * treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) for at least 60 days before screening * glycated haemoglobin (hba1c) 7 percent-10 percent (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as measured by the central laboratory at screening exclusion criteria: for participants without t2d at screening: * hba1c greater than or equal to 6.5 percent (48 mmol/mol) as measured by the central laboratory at screening * history of type 1 or type 2 diabetes mellitus for participants with t2d at screening: * clinically significant or severe hypoglycaemia within 6 months before screening or history of hypoglycaemia unawareness * renal impairment with estimated glomerular filtration rate (egfr) lesser than 30 milli liter per min/1.73 meter square (ml/min/1.73 m\^2), as measured by the central laboratory at screening * uncontrolled and potentially unstable diabetic retinopathy or maculopathy. verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
treatment of hypersensitivity syndrome (dress) with tegeline® (human immunoglobulin)

Conditions: Drug Hypersensitivity

Summary: efficacy and tolerance of tegeline® treatment in hypersensitivity syndrome. immunological study of the t cell index phenotype and functionality in hypersensitivity syndrome.


Eligibility criteria:
inclusion criteria: * age \>= 18 * cutaneous and/or mucous eruption * polyadenopathy * body temperature \> 38°c * hematology disorders : hypereosinophily \> 1.5 g/l, lymphocytosis \> 5g/l, atypical blood lymphocytes * consent obtained from patient exclusion criteria: * age \< 18 * no consent obtained from patient * igv allergy * dress with very sérious visceral attack and vital diagnostic (sharp cardiac insufficiency, sharp respiratory insufficiency, hepatic insufficiency, sharp renal insufficiency) * oral therapy or immunosuppressive therapy (methotrexate, cyclosporine, cyclophosphamide, etc.) * iga deficiency, * mci \>=35 * sharp renal insufficiency before dress with creatinaemia \< 60 ml/min (cockroft)

Keywords: hypersensitivity syndrome tegeline
cut-out of the cervical screw on pertrochanteric fractures

Conditions: Pertrochanteric Fracture

Summary: pertrochanteric fractures are a highly relevant topic not only because of the high frequency or age of the population concerned, but also because of comorbidity (osteoporosis, malnutrition, decreased physical activity, decreased visual acuity, neurological deficits, asthenia, disorders of the equilibrium and impaired reflexes) and the mortality associated with this type of fractures. the cut-out of the cervical screw is a mechanical complication common to different means of osteosynthesis of pertrochanteric fractures, this complication significantly increases the morbidity. from january 2013 to may 2019, out of a total of 340 patients having had surgery for pertrochanteric fracture, 12 cases of cervical screw cut-out were recorded within the brugmann university hospital. the average follow-up after surgery was 18 months. this study analyses different parameters and their link with cervical screw cut-outs, and compares the results with the ones published in the scientific literature.


Eligibility criteria:
inclusion criteria: all patients admitted for a pertrochanteric and subtrochanteric fracture of the femur treated by cerebrospinal nailing with all the methods of fixation of the head (blade or screw) and who evolved to a cut-out of the cervical screw. exclusion criteria: * fractures treated by open osteosynthesis * fractures operated with good radiological outcome * incomplete or non useable medical files
parallel group, placebo-controlled, tolerability, safety, and efficacy study of opc-14117 in hiv dementia

Conditions: Cognitive Disorders; HIV Infections

Summary: to assess the tolerability and safety of opc-14117. to evaluate effects of opc-14117 on cognitive function, quality of life, and activities of daily living.

patients receive opc-14117 or placebo bid for 12 weeks, followed by 12 weeks of open label therapy.

Eligibility criteria:
inclusion criteria patients must have: * hiv seropositivity. * cognitive impairment. prior medication: allowed: * prior opc-14117 other than on the current study. * antiretroviral therapy if stable for 6 weeks prior to study entry (12 weeks for stavudine). exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * current opportunistic cns infection (i.e., toxoplasmosis or cryptococcal meningitis). * severe pre-morbid psychiatric illness including schizophrenia and major depression that would interfere with protocol compliance. * cns neoplasms. * any other clinically significant condition or laboratory abnormality that would interfere with ability to participate on study. * current participation in other drug studies. patients with the following prior conditions are excluded: * past history of opportunistic cns infection (i.e., toxoplasmosis or cryptococcal meningitis). * history of chronic neurological disorders such as serious head injury, documented stroke, multiple sclerosis, uncontrolled epilepsy, tourette's syndrome, and other neurodegenerative processes such as huntington's disease. * history of adverse reaction / allergy to opc-14117. * prior participation on this study. prior medication: excluded: * other investigational drugs within the past 30 days. alcoholism within past 6 months (more than 2 drinks daily).

Keywords: cognition disorders acquired immunodeficiency syndrome aids-related complex free radical scavengers antioxidants opc 14117
obstructive sleep apnea among somali-americans

Conditions: Obstructive Sleep Apnea

Summary: the investigators seek to advance the understanding of obstructive sleep apnea as it relates to different ethnic origins as well as sex differences. the investigators will compare somali patients with known obstructive sleep apnea (osa) to individuals without osa, and to individuals of other ethnic/racial origins to determine the risk factors (genetic and/or physiologic) associated with developing cardiovascular diseases. this will help the investigators to understand the unique sleep pathology of individuals of african descent.

participants can be healthy volunteers or volunteers diagnosed with obstructive sleep apnea. all patients may undergo a sleep study (i.e. hospital or home-based), physical examination, questionnaires, blood and urine samples, ultrasound scan of the heart and brachial artery in the arm, ct scan, dexa scan, paced breathing test, cardiopulmonary test and chemo-sensitivity test.

Eligibility criteria:
inclusion criteria: * self-identify as somali, african, asian, and european descent. * adult males and females who are older than 18 years of age. exclusion criteria: * minors under 18 years or adults over 100 years * positive pregnancy

Keywords: somali-americans sleep disordered breathing cardiovascular diseases sex and racial differences respiratory disorders hypertension diabetes health disparities
open-label safety and efficacy of the sufentanil sublingual tablet 30 mcg for acute pain

Conditions: Moderate-to-severe Acute Pain

Summary: to evaluate the safety and efficacy of sufentanil tablet (st) 30 mcg in the management of moderate-to-severe acute pain in patients in an emergency room (er) setting.

the study is a multicenter, open-label trial, in patients 18 years and older, who present to the er with moderate-to-severe acute pain due to obvious trauma or injury evident on physical examination. upon meeting all entrance criteria, patients will be administered up to four doses of sufentanil 30 mcg and remain in the study for 5 hours for safety and efficacy measurements. safety will be monitored via periodic measurement of vital signs and continuous monitoring of oxygen saturation, as well as assessment of adverse events (aes) and the use of concomitant medications. efficacy will be assessed by patient reports of pain intensity (pi) and pain relief. a six-item screener (sis) will be administered before and 1 hour after study drug administration to measure cognitive impairment. the patient global assessment (pga) and the healthcare professional global assessment (hpga) will assess global satisfaction with the method of pain control.

Eligibility criteria:
inclusion criteria: * patients who present to the er with moderate-to-severe pain due to obvious trauma or injury evident on physical examination. * patients classified as american society of anesthesiologists (asa) class i-iii * patients who are willing and capable of understanding and cooperating with the requirements of the study. * patients able to understand and communicate in english. * patients who have provided written informed consent and signed the irb approved consent form. exclusion criteria: * patients who have taken an opioid for more than 30 consecutive days, at a daily dose of more than 15 mg of morphine (or equivalent), within the past 3 months (e.g. more than 3 doses per day of vicodin®, norco®, lortab® with 5 mg hydrocodone per tablet). * patients who have used any illicit drugs of abuse, abused prescription medication or alcohol (4 or more drinks per day) within one year before the start of the study. * patients with an allergy or hypersensitivity to opioids. * patients who are currently taking monoamine oxidase inhibitors (maois) or have taken maois within 14 days of the dose of study drug. * patients with current sleep apnea that has been documented by a sleep laboratory study or are on home continuous positive airway pressure (cpap). * female patients who are pregnant (positive pregnancy test) or breastfeeding. * patients with a medical condition that, in the investigator's opinion, could adversely impact the patient's participation or safety, conduct of the study, or interfere with the pain assessments, including chronic pain or active infection. * patients who present to the er using supplemental oxygen. * patients who have participated in a clinical trial of an investigational drug or device within 30 days of enrollment. * patients who are active or reserve duty with the us military.
cirrhotic patients with septic shock

Conditions: Septic Shock; Cirrhosis

Summary: cirrhotic patients have a poor outcome in intensive care unit (icu). septic shock is a leading cause of icu admission and death in this specific population. we performed a monocentric retrospective study; all cirrhotic patients admitted in the icu with septic shock from 2002 to 2013 were included. the aim of the study was to identify prognostic factors for both short- and long-term mortality in these patients. demographic, clinical and biological data, organ supports, and outcomes were collected. univariate and multivariate analysis were carried out regarding both icu and one-year mortality.


Eligibility criteria:
inclusion criteria: * age 18 or older * diagnosis of cirrhosis * diagnosis of septic shock at icu admission exclusion criteria: * prior liver transplantation
a pilot, feasibility study of intermittent caloric restriction plus plant-based diet in cancer patients receiving chemotherapy

Conditions: Medical Oncology; Integrative Oncology; Medical Nutrition Therapy

Summary: caloric restriction may alter the response to chemotherapy induced stress response and enhance its antitumor effect. this study intends to use an intermitted caloric restriction protocol with alternate days before the chemotherapy administration to enhance the cytotoxic effect generated by standard treatment of cancer.

this pilot trial will provide preliminary evidence that 1) intermittent caloric restriction and a plant-based diet is feasible in cancer patients; 2) intermittent caloric restriction and a plant-based diet can be safely combined with standard chemotherapy; and 3) intermittent caloric restriction and a plant-based diet may reduce the side effects but increase the antitumor effects of standard chemotherapy.

Eligibility criteria:
inclusion criteria: * • histologically documented, cancer patients who are eligible to receive cytotoxic chemotherapy. * life expectancy of at least 6 months * adults ≥ 18 years of age * adequate hematologic, renal, and liver function as evidenced by the following: * white blood cell (wbc) ≥ 2,500 cells/μl * absolute neutrophil count (anc) ≥ 1,000 cells/μl * platelet count ≥ 100,000 cells/μl * hemoglobin (hgb) ≥ 9.0 g/dl * creatinine ≤ 2.0 mg/dl * total bilirubin ≤ 2 x upper limit of normal (uln) * aspartate aminotransaminase (ast, sgot) ≤ 2.5 x uln * alanine aminotransaminase (alt, sgpt) ≤ 2.5 x uln exclusion criteria: * • eastern cooperative oncology group (ecog) performance status 2 or higher * treatment with any of the following medications or interventions within 28 days of registration: * systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable. * high dose calcitriol \[1,25(oh)2vitd\] (i.e., \> 7.0 μg/week) * any infection requiring parenteral antibiotic therapy or causing fever (temperature \> 100.5°f or 38.1°c) within 1 week prior to registration * a known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified ct/mri imaging * any medical intervention or other condition which, in the opinion of the principal investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives
optimizing functional recovery of breast cancer survivors

Conditions: Breast Cancer Female

Summary: this study is a randomized controlled trial (rct) to test the efficacy of a behavioral activation and problem solving (ba/ps) approach to improving activity participation over time as compared to an attention control condition within a sample of 300 breast cancer survivors reporting reduced activity participation after completing cancer treatment.

assessments will be administered via telephone by a research assistant blind to group assignment. participants will complete outcome assessments upon enrollment (t1) and at 8 weeks (t2), 20 weeks (t3) and 44 weeks (t4) later. the t2 assessment captures the short-term outcomes of the most intensive part of the intervention (i.e., after six weekly sessions). the t3 assessment will capture the short-term outcomes at the end of the full intervention. the t4 assessment explores the sustained effect of ba/ps (six months after ba/ps ends). the study aim is to test whether the ba/ps intervention affects the "slope" of functional recovery over time. with the longitudinal data, the investigators will also be able to explore the pace of improvement and whether the two groups differ at these clinically relevant time points.

Eligibility criteria:
inclusion criteria: 1. age of 18 years or older. 2. experiencing reduced participation (i.e., a score greater than or equal to 10 on the work and social adjustment scale). 3. females diagnosed with stage 1-3 breast cancer and within one year of completion of locoregional treatment and/or chemotherapy with curative intent and absence of disease recurrence exclusion criteria: 1. non-english speaking. 2. non-correctable hearing loss. 3. moderate-severe cognitive impairment indicated by a score \< 3 on a 6-item cognitive screener. 4. history of severe mental illness (i.e., schizophrenia, bipolar disorder), current major depressive disorder, active suicidal ideation, or active substance misuse documented within the medical record.
a dose-ranging, multicenter polysomnography trial of pd 0200390 in adults with primary insomnia

Conditions: Primary Insomnia

Summary: the purpose of this study is to further explore an effective dose range of pd0200390 for the treatment of patients with insomnia.


Eligibility criteria:
inclusion criteria: 3 month history of primary insomnia (dsm-iv criteria) self report sleep criteria for at least 3 nights per week in past month; swaso (subjective wake after sleep onset) equal or greater than 60 mins slso (subjective latency to sleep onset) equal or greater than 45 minutes tst less than or equal to 6.5 hrs maintain normal daytime-awake, nighttime-sleep schedule psg sleep criteria of mean waso equal or greater than 60 mins calculated on 2 psg screening nights tst between 3 to 7 hrs on 2 psg screening nights mean lps (latency to persistent sleep) equal or greater than 20 mins calculated on 2 psg screening nights exclusion criteria: comorbid psychiatric disease or disorders history or presence of breathing-related disorders multivariable apnea risk index (map) equal or greater than 0.5 at screening history or presence of medical or neurological condition interfering with sleep current use of know psychotropic effect medications excessive caffeine use use of alcohol as a sleep aid or more than 2 standard drinks/day
impact of fentanyl analgesia on the accuracy of hvpg measurements in patients with portal hypertension

Conditions: Liver Cirrhosis; Portal Hypertension; Pain

Summary: portal hypertension is a common complication of chronic liver disease and is associated with most clinical consequences of cirrhosis. the most reliable method for assessing portal hypertension is the measurement of the hepatic venous pressure gradient (hvpg). the hvpg is the gold-standard methods for assessing clinically significant portal hypertension and becoming increasingly used clinically. it is useful in the differential diagnosis of portal hypertension and provides a prognostic index in cirrhotic patients. many patients are painful and reluctant to undergo serial hvpg measurements. but interventionists are reluctant to use analgesics because they always pay more attention to the accuracy of hvpg measurements.although adam f. et al concluded that low-dose midazolam sedation is an option for patients undergoing serial hepatic venous pressure measurements (hepatology 1999), the effects of using opioid analgesics alone on hepatic venous pressure measurements have not yet been defined. the objective of this study was to evaluate the effects of fentanyl on the hvpg.

portal hypertension is a common complication of chronic liver disease and is associated with most clinical consequences of cirrhosis. the most reliable method for assessing portal hypertension is the measurement of the hepatic venous pressure gradient (hvpg). the hvpg is the gold-standard methods for assessing clinically significant portal hypertension and becoming increasingly used clinically. it is useful in the differential diagnosis of portal hypertension and provides a prognostic index in cirrhotic patients. many patients are painful and reluctant to undergo serial hvpg measurements. but interventionists are reluctant to use analgesics because they always pay more attention to the accuracy of hvpg measurements. may be since it is difficult to monitor hvpg for anesthesiologist during liver surgery, there are very few and controversial studies on the effects of sedation and analgesics on hvpg. m. susan mandell et al concluded that desflurane alters hvpg measurements, whereas propofol did not change it (anesth analg 2003). however, enric reverter et al considered that deep sedation with propofol and remifentanil adds substantial variability and uncertainty to hvpg measurements (liver international 2013). although adam f. et al concluded that low-dose midazolam sedation is an option for patients undergoing serial hepatic venous pressure measurements (hepatology 1999), the effects of using opioid analgesics alone on hepatic venous pressure measurements have not yet been defined. the objective of this study was to evaluate the effects of fentanyl on the hvpg measurements.

Eligibility criteria:
inclusion criteria: * patients with cirrhosis and portal hypertension undergoing elective tips placement * asaⅰ\~ⅲ exclusion criteria: * patients with portal vein thrombosis and vein-to-vein communications * refusal of consent * presence of allergy to fentanyl

Keywords: hepatic venous pressure gradient fentanyl
evaluation of the effect of high-intensity laser therapy in knee osteoarthritis

Conditions: Knee Osteoarthritis; Laser Therapy; Muscle Strength

Summary: the aim of this study is to evaluate the effects of high intensity laser therapy (hilt) on range of motion, pain, quality of life, muscle strength and femoral cartilage thickness in patients with knee osteoarthritis.

patients who are admitted and diagnosed with knee osteoarthritis based on anamnesis, physical examination and imaging methods are included in the study.

Eligibility criteria:
inclusion criteria: 1-40-70 years old 2-diagnosis of knee oa according to acr clinical and radiological diagnostic criteria 3-kellgren lawrence stage ii or iii 4-knee pain for at least 6 months 5-visual analog scale (vas) score of at least 3 or more exclusion criteria: 1. history of surgery or traumatic injury 2. inflammatory arthritis 3. history of cancer, bleeding diathesis and psychiatric disease 4. those who have a disease that limits their participation in exercises (severe chronic obstructive lung disease, severe heart failure, history of cerebrovascular events) 5. hip and ankle problems 6. participating in another physical therapy program in the last 3 months 7. history of intra-articular injections in the last 6 months